TY - JOUR
T1 - Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer
T2 - Good response with tolerability
AU - Azuma, Haruhito
AU - Inamoto, Teruo
AU - Takahara, Kiyoshi
AU - Ibuki, Naokazu
AU - Koyama, Kohei
AU - Utimoto, Synya
AU - Fujisue, Yutaka
AU - Uehara, Hirohumi
AU - Komura, Kazumasa
AU - Nomi, Hayahito
AU - Ubai, Takanobu
AU - Katsuoka, Yoji
PY - 2010/9
Y1 - 2010/9
N2 - Objectives: This study evaluated the safety profile and therapeutic value of a combination therapy of etoposide and ethinylestradiol, which is a novel treatment protocol for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: Patients were given etoposide (25 mg/day, daily) and ethinylestradiol (3 mg/day, daily) orally until disease progression or unacceptable toxicity. The response rate, survival and safety profiles were evaluated. Results: Between 2003 and 2009, 61 patients were enrolled. In terms of PSA levels, >70% of patients showed a >50% reduction (complete response [CR] 51%, partial response 23%) and >90% showed a clinical response. Of 58 patients with measurable lesions, 24% (14/58) showed a CR, and most of these patients (13/14, 93%) survived without recurrence with median response duration of 28 months Conclusion: The regimen was tolerable, with a significant improvement in quality of life, and produced an effective response in patients with HRPC.
AB - Objectives: This study evaluated the safety profile and therapeutic value of a combination therapy of etoposide and ethinylestradiol, which is a novel treatment protocol for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: Patients were given etoposide (25 mg/day, daily) and ethinylestradiol (3 mg/day, daily) orally until disease progression or unacceptable toxicity. The response rate, survival and safety profiles were evaluated. Results: Between 2003 and 2009, 61 patients were enrolled. In terms of PSA levels, >70% of patients showed a >50% reduction (complete response [CR] 51%, partial response 23%) and >90% showed a clinical response. Of 58 patients with measurable lesions, 24% (14/58) showed a CR, and most of these patients (13/14, 93%) survived without recurrence with median response duration of 28 months Conclusion: The regimen was tolerable, with a significant improvement in quality of life, and produced an effective response in patients with HRPC.
UR - http://www.scopus.com/inward/record.url?scp=77958558517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958558517&partnerID=8YFLogxK
M3 - Article
C2 - 20944163
AN - SCOPUS:77958558517
SN - 0250-7005
VL - 30
SP - 3737
EP - 3746
JO - Anticancer research
JF - Anticancer research
IS - 9
ER -
